GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » 3-Year ROIIC %

Regen BioPharma (Regen BioPharma) 3-Year ROIIC % : 33.59% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Regen BioPharma's 3-Year ROIIC % for the quarter that ended in Sep. 2023 was 33.59%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Regen BioPharma's 3-Year ROIIC % or its related term are showing as below:

RGBP's 3-Year ROIIC % is ranked better than
72.78% of 1418 companies
in the Biotechnology industry
Industry Median: -15.195 vs RGBP: 33.59

Regen BioPharma 3-Year ROIIC % Historical Data

The historical data trend for Regen BioPharma's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma 3-Year ROIIC % Chart

Regen BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.18 1,162.63 25.57 -16.06 33.59

Regen BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 33.59 - -

Competitive Comparison of Regen BioPharma's 3-Year ROIIC %

For the Biotechnology subindustry, Regen BioPharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's 3-Year ROIIC % falls into.



Regen BioPharma 3-Year ROIIC % Calculation

Regen BioPharma's 3-Year ROIIC % for the quarter that ended in Sep. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -0.687 (Sep. 2023) - -0.209 (Sep. 2020) )/( 3.836 (Sep. 2023) - 5.259 (Sep. 2020) )
=-0.478/-1.423
=33.59%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Regen BioPharma  (OTCPK:RGBP) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Regen BioPharma 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma (Regen BioPharma) Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.